Business Insider4y
SPACs have raised $1.3 billion to target the next big biotech startup. They're hitting intense competition and reluctance from startups.
The IPO method will only become more appealing as the market uncertainty caused by the pandemic stabilizes, Karkare said. Multiple companies in Arch Venture Partners' portfolio are speaking to ...